RECRUITING

Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Investigators are conducting a study on alternative treatments for patients who have received an current or previous positive COVID-19 diagnosis with mild-serve symptoms or undiagnosable condition after testing positive for severe acute COVID-19 infection and are experiencing long-haul symptoms. The symptoms of long COVID can include extreme tiredness (fatigue), shortness of breath, memory and concentration issues (brain fog), heart palpitations, dizziness, joint pain, muscle aches, cough, headaches, anxiety, and depression. It's important to note that there are various other symptoms that individuals can experience after a COVID-19 infection, such as loss of smell, chest pain or tightness, difficulty sleeping (insomnia), pins and needles, depression, anxiety, tinnitus, earaches, nausea, diarrhea, stomach aches, loss of appetite, cough, headaches, sore throat, and changes to the sense of smell or taste. To be included in the study, participants must have had symptoms for more than 4 weeks. The goal of the study is to measure biomarkers, identify new ones through clinical trials, and individualize and optimize treatment plans, which may or may not include COVID-19 post-market antivirals, vaccines, and medical care. It's essential to conduct thorough clinical trials to understand the long-term effects of COVID-19 and to develop personalized treatment plans for individuals experiencing long-haul symptoms.

Official Title

Covid-19 Long Haul Syndrome: Undiagnosed Disorder Post Covid-19 Alternative Treatment Study.

Quick Facts

Study Start:2024-03-01
Study Completion:2030-09-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06441955

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Inclusion of Men, Women, and Minorities
  2. * Participants must be at least 18 years old.
  3. * Participants must have a positive COVID-19 diagnosis or clinical diagnosis of COVID-19
  4. * Participants must have experienced persistent symptoms after recovering from the acute phase of the illness.
  5. * Participants must be willing to provide informed consent to participate in the study.
  6. * Participants must be able to communicate effectively in English or have a translator available.
  7. * Participants must be able to attend follow-up appointments as required by the study protocol.
  8. * Participants must not have any medical conditions or take any medications that could interfere with the study results.
  1. * \>18 years of age
  2. * Medical History of Myocarditis
  3. * Medical History of Pericarditis
  4. * Medical History of Severe renal impairment (eGFR \<30 mL/min).

Contacts and Locations

Study Contact

Kawana J Williams, Ph.D.
CONTACT
2406201587
Kawana.williams@waldenu.edu
KENNY WILLIAMS
CONTACT
2676067169
gant2121@gmail.com

Principal Investigator

Kawana J Williams, Ph.D.
PRINCIPAL_INVESTIGATOR
The National Institute of Health All of Us Research Program At Well-Konnect Healthcare Services and Research Center

Study Locations (Sites)

NIH Clinical Center
Bethesda, Maryland, 20892
United States

Collaborators and Investigators

Sponsor: Well- Konnect Healthcare Services and Research Firm

  • Kawana J Williams, Ph.D., PRINCIPAL_INVESTIGATOR, The National Institute of Health All of Us Research Program At Well-Konnect Healthcare Services and Research Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-03-01
Study Completion Date2030-09-30

Study Record Updates

Study Start Date2024-03-01
Study Completion Date2030-09-30

Terms related to this study

Additional Relevant MeSH Terms

  • COVID-19, Long Haul